Edwards Elizabeth Anne, Twiss Jacob, Byrnes Catherine Ann
University of Auckland and Starship Children's Hospital, Department of Respiratory Medicine, Private Bag 92024, Auckland, New Zealand.
Expert Opin Pharmacother. 2004 Jul;5(7):1471-84. doi: 10.1517/14656566.5.7.1471.
Non-cystic fibrosis (CF) bronchiectasis, the abnormal dilatation of bronchial airways, is a heterogeneous condition caused by a variety of lung insults and results in significant morbidity and mortality. Although frequently reported as being an uncommon respiratory disease in the developed world, its impact on the respiratory health of specific populations has recently received increased attention. There are limited data on which to base management strategies. This article reviews the evidence for current treatment practices, provides an opinion on best practice, and discusses likely new therapies. Consideration is also given to the pharmacoeconomic hurdles that face the populations most affected.
非囊性纤维化(CF)支气管扩张是支气管气道的异常扩张,是一种由多种肺部损伤引起的异质性疾病,会导致显著的发病率和死亡率。尽管在发达国家,它常被报道为一种罕见的呼吸系统疾病,但它对特定人群呼吸健康的影响最近受到了更多关注。用于制定管理策略的数据有限。本文回顾了当前治疗方法的证据,对最佳实践提出了意见,并讨论了可能的新疗法。同时也考虑了受影响最严重人群所面临的药物经济学障碍。